Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Source updated2026-02-25Last update listed in the registry record
Version history
Changes to this trial
Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
· 1 field changed
Primary outcomes · main study measures
Text edit · unverified significance
− Previous value
measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).; measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events; measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.; measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS); measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E; measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H
+ Updated value
measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).; measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events; measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.; measure: To Evaluate the Long-term Safety and Tolerability of AL002, by Assessing the Number of Suicidal Risk Events Using the Columbia-Suicide Severity Rating Scale (C-SSRS); measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E by Assessing the Number of Participants With ARIA-E Events; measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H by Assessing the Number of Participants With ARIA-H Events
The saved outcome text may be shortened. Check the source for full wording.
measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).; measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events; measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.; measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS); measure: To Evaluate the Effect of Dose Titration on ARIA-E; measure: To Evaluate the Effect of Dose Titration on ARIA-H
+ Updated value
measure: Safety and Tolerability as Measured by Number of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).; measure: Safety and Tolerability as Measured by Number of Adverse Events of Special Interest and Serious Adverse Events; measure: Safety and Tolerability as Measured by the Number of Cases of Abnormal Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.; measure: To Evaluate the Long-term Safety and Tolerability of AL002 by Assessing Suicidality Using the Columbia-Suicide Severity Rating Scale (C-SSRS); measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-E; measure: To Evaluate the Effect of Dose Titration on the Occurrence of ARIA-H
The saved outcome text may be shortened. Check the source for full wording.
measure: Safety and tolerability as measured by number of/incidence of Adverse Events (AEs), including AESI and SAEs.; measure: Safety and tolerability as measured by the number of incidence/MRI abnormalities.
+ Updated value
measure: Safety and Tolerability as Measured by Number of/Incidence of Treatment-expected Adverse Events (TEAE) and Treatment-related Adverse Events (AEs).; measure: Safety and Tolerability as Measured by Number of/Incidence of Adverse Events of Special Interest and Serious Adverse Events; measure: Safety and Tolerability as Measured in Evaluation of Vital Signs, Clinical Laboratory Results and Findings From Physical, Neurological, Ophthalmological Examinations and Electrocardiograms.; measure: To Evaluate the Long-term Safety and Tolerability of AL002 Utilizing the Columbia-Suicide Severity Rating Scale (C-SSRS); measure: To Evaluate the Effect of Dose Titration on ARIA-E; measure: To Evaluate the Effect of Dose Titration on ARIA-H
The saved outcome text may be shortened. Check the source for full wording.
Trial